Pioneering the future of neurological screening through AI-powered handwriting analysis
BRAINALYSIS is developing breakthrough technology designed to detect Parkinson's, Alzheimer's, and other neurodegenerative diseases 5-10 years before clinical symptoms appear. Our software-only approach makes early neurological screening accessible to everyone, everywhere.
Founded as a strategic partnership with Sheba Medical Center's ARC Innovation Network, we combine cutting-edge AI technology with world-class clinical expertise. Sheba Medical Center, ranked among the top-10 hospitals globally by Newsweek, provides crucial clinical credibility, validation infrastructure, and access to neurological patient data.
Research has shown that handwriting changes can appear years before traditional diagnosis. We're developing deep learning algorithms to analyze these subtle patterns, targeting 85-95% accuracy in early detection. Our technology is being validated through proof-of-concept studies with Sheba's neurology department.
CEO & Co-Founder
20+ years in legal & AI entrepreneurship. Former tech startup founder and legal advisor to healthcare companies. Domain expertise in digital health regulation.
CTO & Co-Founder
30+ years in business, management, strategy, and technology. Former CIO/CTO at 888.com. Entrepreneur and investor in multiple startups.
Chief Medical Advisor
Director, Epilepsy Clinic, Sheba Medical Center. PhD Weizmann Institute. 50+ published papers on neurological disorders.